San Diego company Biolinq has raised $58 million in funding, totaling $178 million to date. The company is creating a wearable patch that measures glucose levels from the intradermal space, an ideal location for sensing biomarkers. This patch is the smallest biosensor in the world and provides real-time feedback directly on the device. Biolinq’s device differentiates from competitors by miniaturizing its technology, measuring more than just glucose, and not causing scar tissue or bleeding. With new funding, Biolinq aims to complete a U.S. pivotal clinical trial and seek FDA clearance for its device.
Source link